TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00915928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dayli for 3 months
Study: NCT03602781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at a dose setting of 75 mcg/kg IBW/hr
Study: NCT02402114
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 120 mg Hydrocortisone given orally one time.
Study: NCT02058212
Drug: ascorbate 1000mg, vitamin E 400, zinc and selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
Study: NCT01183221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Placebo
Study: NCT03752827
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection into subacrominal space
Study: NCT04581512
Drug: EP0042
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP0042 Oral 20 mg 50 mg capsules
Study: NCT00003521
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Soft Tissue Sarcoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT00937378
Drug: SER120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Spray, once a day
Study: NCT01495156
Drug: Placebo/Adjunctive SGA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the placebo /adjunctive SGA group will receive placebo for the entire trial in addition to the adjunctive SGA.
Study: NCT00852969
Drug: Active Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Niacin tablets once per day
Study: NCT02957643
Drug: Iron
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral treatment
Study: NCT02595424
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02349243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg placebo, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
Study: NCT03247517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered once daily
Study: NCT03247517
Drug: 200mg SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg SPN-812 was administered once daily and compared to placebo
Study: NCT03247517
Drug: 400mg SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg SPN-812 was administered once daily and compared to placebo
Study: NCT00678041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
Study: NCT02358343
Drug: Antidepressant Drug Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The site investigators will prescribe sertraline drug at a starting dose of 25 mg oral tablets. Dose titration will be implemented using standardized assessments of depressive symptoms and drug side effects; and the research team and the patient make joint decisions to maintain, increase, or decrease the dose. This will help establish the highest effective but tolerable dose tailored for each patient. The QIDS-SR scale will be used to assess the clinical response for dose titration. The FIBSER scale will be used to assess side effects and the degree to which they interfere with day-to-day functions. The participant-specific dose at week 6, up to a maximum of 200 mg/d, will be continued for the remaining 6 weeks.
Study: NCT03861403
Drug: TRX518
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion
Study: NCT03861403
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by IV infusion
Study: NCT00226421
Drug: Oxymorphone Extended Release
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02015559
Drug: mucoadhesive oral wound rinse
Normalized name: MuGard Mucoadhesive Oral Wound Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03275922
Drug: Placebo ZNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Zolmitriptan Nasal Spray
Study: NCT03275922
Drug: ZNS
Normalized name: ZnSO4 3 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan Nasal Spray
Study: NCT04054960
Drug: Levodopa tablet
Normalized name: Levodopa Tablets
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: We will give 3 tablets of Levodopa-Carbidopa (100/25).
Study: NCT04132336
Drug: Naproxen sodium/Caffeine (BAY2880376)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral, single dose
Study: NCT04132336
Drug: Naproxen sodium (Aleve)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, oral, single dose
Study: NCT04132336
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, oral, single dose
Study: NCT04132336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral, single dose
Study: NCT00433290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo every day (QD), by mouth (PO) for 13 weeks
Study: NCT01107457
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT04008186
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg tablet
Study: NCT00974974
Drug: IPX066
Approvals — FDA: no, EMA: no, PMDA: no
Description: extended-release carbidopa-levodopa capsules
Study: NCT00974974
Drug: IR CD-LD
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: immediate-release carbidopa-levodopa tablets
Study: NCT01892657
Drug: Facial Moisturizer with SPF 50+
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+
Study: NCT02613013
Drug: Proparacaine
Normalized name: proparacaine
DrugBank: Proparacaine (DB00807)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
Study: NCT02773459
Drug: MEK162+capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.
Study: NCT00713999
Drug: Treatment with anti-STI and anti-schistosoma regimens
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg
Study: NCT00132093
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01916590
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01736241
Drug: LY3053102
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01736241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00688376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the 12-week Double-Blind Phase, subjects will receive matching placebo tablets (3, 5, of 10 mg) once daily.~During the 12-week Blinded Extension Phase, all subjects will receive active treatment (donepezil).
Study: NCT02770885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with Sodium Chloride 0.9% (Placebo) for 3 weeks.
Study: NCT03837938
Drug: Levopront® syrup 30 mg/5 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1).
Study: NCT03837938
Drug: Libexin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1). No chewing.
Study: NCT01415765
Drug: MLN4924
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: 150mg/m2 IV (in the vein) on days 1,4,7,11 of each 21 day cycle Part B: variable dose levels IV on days 1,5 each 21 day cycle
Study: NCT01415765
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV on day 5 of each 21 day cycle
Study: NCT00592839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for 0.3 mg and 0.625 mg tablets
Study: NCT01415765
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CIV on days 1-4 of each 21 day cycle
Study: NCT00004230
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02858258
Drug: R-CHOP/R-DHAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)
Study: NCT01131572
Drug: N-acetylcysteine NAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine in the treatment of Bulimia Nervosa
Study: NCT02858258
Drug: ASCT conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASCT conditioning THAM or BEAM, stratified per site before trial activation at site~THAM (TBI (total body irradiation), Ara-C, Melphalan) or~BEAM (BCNU, Etoposide, Cytarabine, Melphalan)
Study: NCT00308685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00816361
Drug: MEDI-573
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.
Study: NCT03598192
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil has been included in Arm/Group Descriptions
Study: NCT00128414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets identical in colour, shape, and taste were provided in blister packs.
Study: NCT03664895
Drug: Leuplin or zoladex
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFS(Leuplin or zoladex) add on to TMX
Study: NCT03080415
Drug: Combined Therapy SOF and DCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day~SOF dosage: 400 mg/day for greater than 45 kg weight patients; 200 mg/day for 17 kg to 45 kg patients~DCV dosage: 60 mg/day for greater than 45 kg weight patients; 30 mg for 17 kg to 45 kg patients
Study: NCT00436709
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00436709
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03233230
Drug: M2591 25 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 12 weeks.
Study: NCT03233230
Drug: M2951 75 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 75 mg of M2951 orally QD for 12 weeks.
Study: NCT03233230
Drug: M2951 50 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 50 mg of M2951 orally twice daily (BID) for 12 weeks.
Study: NCT03233230
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched to M2951 orally for 12 weeks.
Study: NCT01019928
Drug: AZD1386
Approvals — FDA: no, EMA: no, PMDA: no
Description: 95 mg, oral solution, single dose
Study: NCT01019928
Drug: Placebo to AZD1386
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral solution, single dose
Study: NCT02838810
Drug: Nucleoside analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside analogues
Study: NCT00643136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules twice daily for 28 days
Study: NCT00757848
Drug: AZD9668 Placebo equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Match placebo to 60 mg, oral tablet, twice daily for 28 days
Study: NCT00845000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, oral, at hour 0 of treatment period
Study: NCT00845000
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
Study: NCT01831453
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: soft gelatinous capsules filled with isopropylmyristate oil
Study: NCT02581007
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.
Study: NCT02516904
Drug: CD101 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: antifungal
Study: NCT00001713
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03812328
Drug: SelK2
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V., single-dose
Study: NCT03461861
Drug: AGB101 220 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.
Study: NCT03512262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abaloparatide-matched placebo.
Study: NCT02013375
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (50 mg/kg IBW) IV, over approximately 1-2 hours, is given on Day 3 post-transplantation (ideally between 60 and 72 hours after marrow infusion) and on Day 4 (approximately 24 hours after Day 3 cyclophosphamide).
Study: NCT03045471
Drug: R-EPOCH
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Etoposide: a topoisomerase inhibitor from the group of epipodofyllotoxins; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
Study: NCT03045471
Drug: R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
Study: NCT00777127
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
Study: NCT02520752
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02520752
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02198326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03407430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the first chemotherapy cycle, the patient will receive placebo (1 capsule) BID x 4 days before pegfilgrastim 6mg SC x1; then placebo (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive pregabalin in the same dosing scheme.
Study: NCT02643017
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of same amount of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
Study: NCT03738215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplied in capsules
Study: NCT02148627
Drug: LY3041658 (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02148627
Drug: LY3041658 (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as slow IV infusion
Study: NCT02148627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as slow IV infusion
Study: NCT02302456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 10 mL of 0.9% sodium chloride solution within 2 minutes of birth and routine prophylactic IV injection of oxytocin
Study: NCT01033071
Drug: Azilsartan medoxomil and chlorthalidone
Normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.
Study: NCT01033071
Drug: Azilsartan medoxomil and chlorthalidone
Normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.
Study: NCT05332028
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patient-controlled analgesia
Study: NCT00281671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride infusion
Study: NCT00684489
Drug: clinical hypertension specialist-no specific med. Any anti-hypertension meds.
Approvals — FDA: no, EMA: no, PMDA: no
Description: assignment to a clinical hypertension specialist. Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, ditiazem, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, clonidine, clonidine patch, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
Study: NCT00684489
Drug: renin guided therapeutics-no specific med. Any anti-hypertensive med.
Approvals — FDA: no, EMA: no, PMDA: no
Description: renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide, polythiazide, indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, chlonidine, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
Study: NCT01271751
Drug: GFT505 80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
Study: NCT01271751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard gelatin capsules, oral administration, 4 capsules per day before breakfast
Study: NCT00222989
Drug: PPI
Normalized name: PPIase
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00850642
Drug: GSK2190195 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.